{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:29:45Z","timestamp":1787167785824,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015728","name":"Clinical Science Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK2 CX002105"],"award-info":[{"award-number":["IK2 CX002105"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.xkme.2025.101089","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T09:28:37Z","timestamp":1755509317000},"page":"101089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Galectin-3 Is Associated With Risk of Cardiovascular and Kidney Outcomes in Ambulatory Veterans"],"prefix":"10.1016","volume":"7","author":[{"given":"Shreya","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav S.","family":"Garimella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly N.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Bullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori B.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-1152","authenticated-orcid":false,"given":"Nicholas","family":"Wettersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xkme.2025.101089_bib1","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.xkme.2025.101089_bib2","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archinte.167.11.1130","article-title":"Cardiovascular disease and subsequent kidney disease","volume":"167","author":"Elsayed","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.xkme.2025.101089_bib3","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1681\/ASN.2014101034","article-title":"Cause-specific deaths in nondialysis-dependent CKD","volume":"26","author":"Navaneethan","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2025.101089_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100604","article-title":"CKD progression risk and subsequent cause of death: a population-based cohort study","volume":"5","author":"Rai","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.xkme.2025.101089_bib5","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.xkme.2025.101089_bib6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/eurjhf\/hfp097","article-title":"Galectin-3: a novel mediator of heart failure development and progression","volume":"11","author":"de Boer","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.xkme.2025.101089_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cardfail.2015.10.022","article-title":"Prognostic value of galectin-3 for adverse outcomes in chronic heart failure","volume":"22","author":"French","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.xkme.2025.101089_bib8","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.jacc.2019.02.046","article-title":"Galectin-3 levels and outcomes after myocardial infarction: a community study","volume":"73","author":"Asleh","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.xkme.2025.101089_bib9","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1016\/j.jacc.2018.09.076","article-title":"Longitudinal change in galectin-3 and incident cardiovascular outcomes","volume":"72","author":"Ghorbani","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.xkme.2025.101089_bib10","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.xkme.2025.101089_bib11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ahj.2013.12.031","article-title":"Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study","volume":"167","author":"Daniels","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.xkme.2025.101089_bib12","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1681\/ASN.2012090909","article-title":"Elevated galectin-3 precedes the development of CKD","volume":"24","author":"O\u2019Seaghdha","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2025.101089_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13054-021-03878-x","article-title":"Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission","volume":"26","author":"Boutin","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.xkme.2025.101089_bib14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1478-7954-4-2","article-title":"Accuracy and completeness of mortality data in the Department of Veterans Affairs","volume":"4","author":"Sohn","year":"2006","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.xkme.2025.101089_bib15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cca.2017.11.018","article-title":"One-year in vitro stability of cardiac troponins and galectin-3 in different sample types","volume":"476","author":"Egger","year":"2018","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.xkme.2025.101089_bib16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.clinbiochem.2010.02.001","article-title":"Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure","volume":"43","author":"Christenson","year":"2010","journal-title":"Clinical Biochemistry"},{"key":"10.1016\/j.xkme.2025.101089_bib17","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"2004"},{"key":"10.1016\/j.xkme.2025.101089_bib18","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and Cystatin C\u2013Based Equations to Estimate GFR without Race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2025.101089_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"12_Supplement","key":"10.1016\/j.xkme.2025.101089_bib20","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0735-1097(25)02270-3","article-title":"Galectin-3 and cardiovascular and kidney outcomes: individual patient data metaanalysis of 74,358 patients from 5 multinational clinical trials","volume":"85","author":"Haller","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.xkme.2025.101089_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cardfail.2022.09.017","article-title":"Galectin-3, acute kidney injury and myocardial damage in patients with acute heart failure","volume":"29","author":"Horiuchi","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.xkme.2025.101089_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031607","article-title":"Galectin-3, metabolic risk, and incident heart failure: the ARIC study","volume":"13","author":"Echouffo-Tcheugui","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.xkme.2025.101089_bib23","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.xkme.2025.101089_bib24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/biomedicines10030585","article-title":"Urinary galectin-3 as a novel biomarker for the prediction of renal fibrosis and kidney disease progression","volume":"10","author":"Ou","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.xkme.2025.101089_bib25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.cardfail.2023.05.018","article-title":"Association of urine galectin-3 with cardiorenal outcomes in patients with heart failure","volume":"30","author":"Rao","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.xkme.2025.101089_bib26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jacbts.2019.06.005","article-title":"Acute kidney injury induces remote cardiac damage and dysfunction through the galectin-3 pathway","volume":"4","author":"Prud\u2019homme","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.xkme.2025.101089_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000962","article-title":"Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis","volume":"3","author":"Meijers","year":"2014","journal-title":"J Am Heart Assoc"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525001256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525001256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:32:59Z","timestamp":1772915579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525001256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2590059525001256"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101089","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galectin-3 Is Associated With Risk of Cardiovascular and Kidney Outcomes in Ambulatory Veterans","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.","name":"copyright","label":"Copyright"}],"article-number":"101089"}}